Litigation Details for Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

✉ Email this page to a colleague

Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

Docket	⤷ Start Trial	Date Filed	2016-03-25
Court	District Court, D. Delaware	Date Terminated	2018-07-24
Cause	35:271 Patent Infringement	Assigned To	Kent A. Jordan
Jury Demand	None	Referred To
Patents	8,148,374
Link to Docket	External link to docket

Small Molecule Drugs cited in Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc.

The small molecule drugs covered by the patent cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-25				External link to document
2016-03-25	4	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,148,374 B2;. (dmp, ) (Entered…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware	External link to document
2016-03-25	79	Notice (Other)	M.D. Fortunak, Ph.D. on Invalidity of U.S. Patent No. 8,148,374 and supporting materials by Mylan Pharmaceuticals…2016 24 July 2018 1:16-cv-00192 830 Patent None District Court, D. Delaware	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation summary and analysis for: Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2016)

Last updated: July 25, 2026

Gilead Sciences v. Mylan (1:16-cv-00192): Litigation Summary, Patent Issues, and Generic Launch Risk

Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc., No. 1:16-cv-00192, is a Hatch-Waxman patent infringement action tied to Mylan’s ANDA and associated Paragraph IV challenges to Gilead’s patents covering an HCV direct-acting antiviral product. The case is best characterized as a standard ANDA patent dispute: plaintiff Gilead asserts infringement of listed Orange Book patents; defendant Mylan asserts non-infringement, invalidity, and/or statutory non-violation tied to its proposed ANDA product.

Bottom line: The litigation record drives (1) which Gilead patents bar early generic entry and (2) the earliest feasible generic launch path once any asserted patent is found invalid, not infringed, or otherwise cleared via settlement and/or final judgment.

What is the case caption, court, and procedural posture for Gilead v. Mylan 1:16-cv-00192?

Answer: The matter is docketed as Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc., 1:16-cv-00192. The litigation is a federal Hatch-Waxman dispute concerning infringement of Gilead’s Orange Book-listed patents by Mylan’s ANDA product.

Key litigation elements that typically control the posture in this docket class

Complaint by Gilead asserting infringement of one or more Orange Book patents tied to the NDA product.
ANDA-related defenses by Mylan tied to Paragraph IV certification.
Early motion practice on pleadings, jurisdiction, and claim construction.
Claim construction and trial or dispositive motions on infringement/validity.
Final judgment and any post-judgment remedies and timelines for generic market entry.

Why posture matters for exclusivity risk In HCV ANDA cases, the practical “clock” is not just the NDA’s statutory exclusivity windows. It is the outcome of asserted patents: each patent decision can independently open or delay market entry. Settlement terms, if any, then define the real-world launch date.

Which patents are asserted in Gilead v. Mylan 1:16-cv-00192 and how do they map to Orange Book listings?

Answer: The litigation’s patent set is defined by Gilead’s Orange Book listings for the relevant NDA and the patents Mylan attacked in its Paragraph IV notice.

How to interpret the patent-to-ANDA mapping

Gilead identifies asserted patents in the complaint, typically corresponding to Orange Book entries for the NDA product.
Mylan’s Paragraph IV notice identifies which of those patents it challenges and on what grounds.
The litigation proceeds patent-by-patent, often with distinct claim sets for active ingredient, formulation, and/or method-of-use.

Operational risk lens For generic entry forecasting, the highest-impact patents are usually:

Composition or active-ingredient claims (harder to design around).
Method-of-use claims (can be avoided by labeling/design if the ANDA’s labeling omits the protected method, subject to the “carve-out” rules).
Formulation or dosage form claims (sometimes design-around is feasible, depending on claim scope and stability/solubility constraints).

What patents protect Gilead’s HCV drug in Hatch-Waxman disputes like this one?

Answer: For Gilead’s HCV portfolio, patent estates commonly include claims covering:

active pharmaceutical ingredient (API) and pharmaceutical compositions
solid-state forms, polymorphs, salts, and formulation approaches
therapeutic regimen or method-of-treatment claims (patient populations and dosing sequences)

How claim types translate into litigation outcomes

API/composition claims: invalidity and non-infringement must be established because generic design-around is constrained.
Method-of-use claims: litigation can narrow around labeling and infringement-by-use.
Formulation claims: can be avoided if a generic uses a different formulation strategy that avoids each claim limitation.

What does Mylan typically argue in Paragraph IV Hatch-Waxman cases like this one?

Answer: In this litigation class, Mylan’s defenses generally include:

Invalidity (anticipation/obviousness under 35 U.S.C. § 102/103; sometimes lack of written description/enablement under § 112)
Non-infringement (ANDA product does not meet claim limitations; process/formulation differences)
No legal infringement based on labeling, carve-outs, or proposed use

Practical impact The strongest defense is usually invalidity of asserted patents, because a final invalidity judgment can clear multiple defendants and downstream applicants tied to similar Orange Book entries.

How does Gilead v. Mylan 1:16-cv-00192 handle claim construction and infringement analysis?

Answer: Hatch-Waxman disputes typically hinge on claim construction that determines whether Mylan’s ANDA product meets the asserted claim limitations.

Common claim-construction pressure points

interpretation of drug substance definitions (salt/form/polymorph scopes)
meaning of formulation parameters (particle size, dissolution profile, excipient selection)
scope of method-of-use language (specific patient attributes and dosing regimen)

Why it matters for generic risk A claim-construction order can narrow or broaden infringement coverage. It often drives settlement economics because it changes probability-weighted outcomes for both sides.

When does the litigation affect generic exclusivity and “at-risk” launch timing?

Answer: The litigation outcome affects whether Mylan can launch “at risk” before all relevant Orange Book patents are cleared.

Typical timing mechanics in Hatch-Waxman

Automatic stay: if Mylan filed a Paragraph IV ANDA, a 30-month stay ordinarily applies while the infringement suit is pending.
Final judgment: outcomes on infringement/validity determine whether the stay converts into a permanent bar (if infringed) or lifts earlier (if invalid/not infringed).
Settlement: may specify a date for generic entry even if appeals remain.

Commercial translation For market-entry forecasting, the relevant date is the last surviving asserted patent. If multiple patents are asserted, the last one cleared sets the practical launch ceiling.

What settlement or final judgment outcomes define the market entry risk in 1:16-cv-00192?

Answer: This litigation’s real-world consequence is defined by:

district court judgment (infringement and/or invalidity decisions)
any appeal and appellate affirmance/reversal
any settlement that sets an agreed entry date and limits collateral estoppel exposure

If the case ended in a patent-infringement outcome

Generic launch is blocked until patent expiration unless design-around or labeling carve-outs are used and adjudicated.
Licensing may still occur but is less common if the court finds broad infringement and validity.

If the case ended in a non-infringement or invalidity outcome

The stay terminates and the generic can launch earlier.
Remaining non-asserted patents could still delay entry.

What is the Orange Book status of the asserted patents in Gilead v. Mylan?

Answer: Orange Book status controls the scope of the Paragraph IV dispute. In this litigation structure, the asserted patents are those listed by Gilead for the NDA and attacked by Mylan in its ANDA certification.

How to use Orange Book status in a litigation analysis

Identify the patent numbers and their expiration dates.
Identify whether each patent is for drug substance, drug product, or method of use.
Tie each patent category to likely litigation defenses and design-around feasibility.

Which companies are involved beyond the named parties, and how does that affect enforcement?

Answer: This docket is captioned with Gilead Sciences Inc. as plaintiff and Mylan Pharmaceuticals Inc. as defendant. The practical enforcement and market-impact footprint can extend to co-defendants or related generics only if they are in the same litigation or if settlement agreements bind other ANDA filers.

Litigation portfolio effect Even where only one generic party is named, the patent findings can influence other ANDA applicants targeting the same Orange Book-listed patents.

How strong is Gilead’s patent estate in cases like this, based on typical HCV DAA strategies?

Answer: Gilead’s HCV patent estates generally include layered coverage: composition and formulation protections plus method-of-use protections tied to dosing regimens. That layering increases odds that at least one asserted patent survives early challenges, especially if broad composition or solid-state claims remain valid.

How to read “strength” in a litigation-specific way

A strong estate usually shows up as: multiple asserted patents, overlapping claim scope, and district court findings that withstand invalidity theories.
Litigation strength depends on claim construction outcomes and the specific prior art landscape for the asserted claims, not just general portfolio size.

How does 1:16-cv-00192 compare with other HCV ANDA patent litigations involving Gilead?

Answer: The case aligns with a common HCV ANDA pattern:

Gilead sues on Orange Book patents after Paragraph IV notices.
The court evaluates infringement and validity of each asserted patent.
The settlement or final judgment translates into an entry date that shapes competitive dynamics.

Competitive implication Cases with similar defendants and similar timing frequently determine the first wave of generic/HCV DAA competition, with downstream effects on pricing and payer contracts.

What generic entry risks exist for Mylan and other applicants if Gilead wins or loses 1:16-cv-00192?

Answer:

If Gilead wins on validity and infringement

Mylan’s ANDA launch is blocked until patent expiration for the last surviving asserted patent.
Other ANDA filers face similar blocking patents even if not party to the suit.

If Mylan wins on invalidity or non-infringement

Mylan’s launch date accelerates (subject to other remaining patents).
Competitors can launch sooner once the patent barrier is removed, compressing exclusivity economics.

If a settlement sets a delayed entry

Launch is moved to the settlement date, not the court’s theoretical earliest date.
Settlement can establish de facto exclusivity for a period longer than court deadlines if the agreement includes side-conditions.

Key Takeaways

Case type: Hatch-Waxman ANDA patent infringement dispute under No. 1:16-cv-00192.
Patent mechanics: The asserted patents are defined by Orange Book listings and Mylan’s Paragraph IV challenges.
Market impact: The operative determinants of generic timing are the last surviving asserted patent and any settlement terms that set an agreed entry date.
Commercial risk: Generic entry probability depends on claim construction and the district court validity/infringement outcomes, followed by any appeals and finality.

FAQs

1) What is the significance of the 30-month stay in Gilead v. Mylan-style ANDA litigation?
It delays final FDA approval-based marketing for the generic until the statutory litigation period concludes, typically aligning launch timing with district court outcomes or settlement.

2) Do method-of-use patents allow labeling carve-outs that avoid infringement?
Often yes in principle, but infringement-by-use and claim scope analysis determine whether a carve-out avoids liability for the protected method.

3) What usually matters most for generic launch timing after a district court decision?
The status of all asserted patents on appeal and any settlement entry dates, because any remaining enforceable patent can block launch.

4) Can an invalidity judgment help other generics besides the defendant?
Yes, once a patent is held invalid in a final judgment, it can remove the legal barrier for other applicants targeting the same claims, subject to procedural posture and preclusion limits.

5) How do formulation patents change the design-around calculus versus active-ingredient patents?
Formulation patents can be avoided by changing excipients, processes, or solid-state attributes if the alternate product does not meet claim limitations; active-ingredient claims are harder to avoid.

References (APA)

U.S. District Court (case docket). Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc., No. 1:16-cv-00192.

More… ↓

⤷ Start Trial